A recent study showed that COVID-19 quarantining has led to people going to bed later, getting up earlier, and getting lower quality sleep, the impact of the COVID-19 pandemic on patients with narcolepsy has not yet been determined.
Obesity, night eating, parasomnia, sleep talking and drunkenness, and ADHD symptoms are more frequent in children than adults at narcolepsy diagnosis.
The FDA has approved Xywav™ oral solution for the treatment of cataplexy or EDS in patients aged ≥7 years with narcolepsy.
Positive topline data from the phase 3 REST-ON trial evaluating FT218 (Avadel), an investigational, once-nightly formulation of sodium oxybate, showed that the treatment led to clinically meaningful improvement in patients with narcolepsy.
Researchers suggest the Narcolepsy Severity Scale be used more frequently in the clinical settings and future narcolepsy studies.
The FDA has accepted for Priority Review the New Drug Application for JZP-258 for the treatment of cataplexy or excessive daytime sleepiness in patients aged ≥7 years with narcolepsy.
Depression, negative social stigma, and dissatisfaction with current clinical care can have an impact on health-related quality of life in patients with narcolepsy.
Solriamfetol offers short-term improvements in functional status, health-related quality of life, and work productivity in people with narcolepsy.
Researchers find treatment with pitolisant is associated with reductions in excessive daytime sleepiness and cataplexy over a 1-year period in patients with narcolepsy.
Treatment with pitolisant, a potent and highly selective H3-receptor antagonist/inverse agonist, reduces excessive daytime sleepiness and cataplexy in patients with narcolepsy.
